Share This Page
Drugs in ATC Class B01AX
✉ Email this page to a colleague
Drugs in ATC Class: B01AX - Other antithrombotic agents
| Tradename | Generic Name |
|---|---|
| DEFITELIO | defibrotide sodium |
| ARIXTRA | fondaparinux sodium |
| FONDAPARINUX SODIUM | fondaparinux sodium |
| >Tradename | >Generic Name |
Patent landscape and market dynamics for ATC Class B01AX (Other antithrombotic agents)
ATC Class B01AX (“Other antithrombotic agents”) spans multiple active ingredients and drug types, with patent estates that are ingredient-, route-, and indication-specific. In practice, exclusivity and generic risk are driven less by the ATC bucket and more by (i) whether the product is a direct thrombin inhibitor, factor Xa inhibitor, antiplatelet adjunct, or niche antithrombotic; (ii) whether the product has meaningful method-of-use coverage; (iii) Orange Book listing density in the US; and (iv) litigation posture tied to Paragraph IV filings.
For market players, the operational takeaway is that “B01AX” is a categorization lens, not a single IP regime. A defensible competitive posture requires product-by-product mapping of Orange Book patents (US) and national phases (EP/GB/DE/FR/IT/ES, plus KR/JP/CN where relevant), followed by a claim charting workflow focused on (a) active-ingredient (composition) claims, (b) formulation claims (salt/polymorph, release, coating, excipients), and (c) method-of-use claims tied to specific clinical contexts (often dosing regimens or patient populations).
Which drugs fall under ATC B01AX and how do their patent estates differ?
ATC B01AX is the “other antithrombotic agents” category. It is heterogeneous by design: it can include single-ingredient anticoagulants and other antithrombotic compounds not placed in B01AA/B01AB/B01AC/B01AE/B01AF/B01AG etc. That heterogeneity is why IP strength varies sharply across the category.
What drives different patent strategies across B01AX ingredients?
- Small-molecule anticoagulants: IP is usually anchored in composition-of-matter (compound/salt) and manufacturing or crystalline form claims, with additional layers for specific dosing regimens and patient-use strategies.
- Adjunct antithrombotic agents: IP may emphasize formulations and combination regimens, with method-of-use claims tied to specific clinical workflows.
- Niche or legacy actives: Patents may be sparse post-2010s, but formulation and process patents can keep branded supply protected in specific regions.
Key implication for diligence
B01AX-level mapping without ingredient-level granularity risks mispricing generic launch timing and underestimating the share of exclusivity held in formulation and method-of-use claims.
How many patents protect B01AX antithrombotic drugs on the US Orange Book, and what patterns show up?
Featured-snippet answer: B01AX products typically show Orange Book patent coverage clustered into three groups: (1) active ingredient composition-of-matter, (2) formulation or salt/polymorph, and (3) method-of-use. The count and persistence of these groups vary by product vintage and whether the sponsor pursued continuing prosecution to expand claim scope.
Typical Orange Book listing patterns for antithrombotics
- Active ingredient patents
- Often the earliest to expire, setting a baseline end-date for composition protection.
- Formulation and manufacturing patents
- Can extend practical exclusivity even after compound expiry, especially for specific salts, polymorphs, or release profiles.
- Method-of-use and dosing regimen patents
- Can block “non-infringing” generic launches if the approved label sits within the protected use.
Risk signal: dense method-of-use listings
When a brand’s Orange Book list includes multiple method-of-use patents with overlapping claim scope, generic risk rises even if the compound patent has expired or is near expiry.
When does exclusivity end for B01AX antithrombotic drugs: patent expiration vs regulatory exclusivity?
Featured-snippet answer: The end of protection for a B01AX product often reflects a two-layer timeline: (i) patent expiration (including any pediatric extensions) and (ii) regulatory exclusivities (new chemical entity, new molecular entity, orphan drug, pediatric, and/or exclusivity tied to other regulatory milestones). In most cases, patent expiry controls Paragraph IV feasibility, not exclusivity alone.
Timeline mechanics
- Regulatory exclusivity (if applicable): can delay ANDA submission and market entry even before patent expiry.
- Patent expiry: drives whether an ANDA can be filed with Paragraph IV and whether settlement is commercially rational.
- Pediatric exclusivity (6 months): can extend the effective “entry window” when triggered.
Operational window
For market entry planning, sponsors model:
- Hard stop: the latest expiration among relevant Orange Book patents tied to an approved label.
- Soft stop: practical litigation duration and “at-risk” entry decisions influenced by injunction likelihood.
Which Paragraph IV challenges have been filed for B01AX antithrombotic drugs, and what settlement patterns matter?
Featured-snippet answer: For B01AX antithrombotics, Paragraph IV outcomes typically cluster into one of three settlement structures: (1) no-entry or delayed-entry settlements, (2) design-around or label carve-out settlements, and (3) “at-risk” outcomes where the generic launches and litigates on invalidity/non-infringement.
What to look for in litigation dockets (high signal)
- Who is the first filer for the relevant ANDA/NDA route and strength.
- Whether the asserted patents are method-of-use or formulation
- Method-of-use assertions are more likely to result in label carve-outs.
- Formulation assertions are more likely to trigger changes in salt form or manufacturing controls.
- Whether the brand obtained a preliminary injunction
- If an injunction is granted, settlement pressure increases.
Settlement terms that shift market share
- Authorized generic (AG) arrangements can preserve revenue to the brand sponsor while allowing competition.
- Co-promotion or supply agreements can redirect revenue flows without breaking legal constraints.
- Staggered entry across strengths or dosing schedules reduces immediate category substitution.
What formulations are protected for B01AX antithrombotic agents (salts, polymorphs, and release systems)?
Featured-snippet answer: For B01AX antithrombotics, formulation protection most commonly covers specific salts and crystalline forms, plus manufacturing controls that define the solid-state profile and bioavailability.
Formulation IP coverage buckets
- Salt forms
- Claims on specific counterions and their crystallinity/bioequivalence parameters.
- Polymorphs and hydrates/solvates
- Solid-state form claims can be difficult to design around if process controls lock in form.
- Particle size and morphology
- Links to dissolution rate and exposure.
- Release profile
- Less common in this class but relevant if the product is modified-release or has tailored dissolution.
Manufacturing process claims
Even if composition claims expire, manufacturing patents can still support injunction or leverage in settlement if the generic must replicate a specific process step covered by claims.
Do B01AX antithrombotic drugs have method-of-use patents that block label-based generic entry?
Featured-snippet answer: Yes, method-of-use patents are often the last “blockers” for B01AX antithrombotic generics because they can be asserted against dosing regimens and patient subgroups on the approved label.
Where method-of-use claims concentrate
- Dosing regimens (mg schedule, titration, duration)
- Patient subgroups (renal impairment adjustments, age, comorbidities)
- Clinical indications aligned with the brand’s label history
Design-around risk
If a generic cannot carve out protected use without changing its label, the generic may be forced into either delayed entry or litigation.
How does the biosimilar and biologics risk profile apply to B01AX?
Featured-snippet answer: B01AX is largely small-molecule focused. Biosimilar frameworks apply only if an ATC B01AX-labeled product is a biologic, which is uncommon for this class.
If biologics exist in the B01AX mapping
- Exclusivity is governed by the Biologics Price Competition and Innovation Act (BPCIA), including interchangeability considerations.
- Market access timing is driven by a different patent and regulatory system than ANDAs.
Practical diligence lens
Treat biosimilar analysis as a conditional branch. The default plan for B01AX is ANDA-style patent and Paragraph IV risk assessment for small molecules.
How does ATC B01AX compare with other antithrombotic ATC categories in terms of patent churn and generic entry speed?
Featured-snippet answer: Compared with more populated antithrombotic subclasses, B01AX often shows fewer high-volume entrants and slower generic “wave” behavior because the category is dispersed among niche compounds with individualized patent estates.
Category-to-category differences
- Large subclasses (e.g., common factor Xa inhibitors): more generic filings, more predictable settlement cycles, faster category substitution.
- B01AX: narrower competitive sets per ingredient, fewer filings, higher likelihood of ingredient-specific litigation bottlenecks.
Competitive landscape outcome
Brand-sponsored strategies in B01AX frequently rely on:
- maintaining dense Orange Book coverage at US launch,
- protecting specific salt/polymorph/formulation pathways, and
- defending method-of-use claims that constrain label carve-outs.
What regulatory pathway facts matter for B01AX (NDA vs ANDA, 505(b)(2), and label carve-outs)?
Featured-snippet answer: For B01AX antithrombotics, generic entry timing depends on whether applicants can use ANDA (ANDA-eligible) versus 505(b)(2) (where reliance on literature or reference product can shift exclusivity and patent use). Label carve-outs can also be decisive if method-of-use patents are asserted.
High-leverage regulatory and legal junctions
- Orange Book patent listing triggers: determines whether a Paragraph IV certification can be made and what claims are at issue.
- Carve-out feasibility: depends on whether the protected use is the only label pathway the sponsor can safely remove without losing therapeutic positioning.
- Bioequivalence: especially relevant if formulation patents force generic to change solid-state form.
Where do B01AX antithrombotic brands make the most money, and how does patent expiry shift revenue exposure?
Featured-snippet answer: Revenue exposure concentrates in the specific approved indication(s) and dose strengths where the label is least carve-out-friendly and where clinicians maintain switching inertia.
Commercial mechanics
- Patent expiry creates entry probability, not instant share loss. Brands defend through:
- managed access contracts,
- substitution controls in formularies,
- and launch timing across strengths to reduce substitution impact.
Revenue risk is strength- and label-specific
A generic may launch on one strength and delay on others if the patent list differs by strength or if method-of-use coverage varies by label revision history.
Key takeaways on patent strength and generic entry barriers for ATC B01AX
- B01AX is not a single patent landscape. Treat it as a container and run the analysis ingredient-by-ingredient.
- Patent protection commonly spans compound/salt, solid-state or formulation controls, and method-of-use/dosing regimens.
- The last enforceable barriers for generics are frequently method-of-use and formulation-linked protections that constrain label carve-outs and bioequivalence.
- Litigation outcomes are typically shaped by which patent family is asserted (method-of-use vs formulation vs manufacturing process) and by whether preliminary injunction risk is high.
- Market dynamics reflect settlement structures, authorized generic strategies, and strength-specific entry plans, not just patent expiration dates.
FAQs
1) What types of patents most often block generic entry for antithrombotic drugs in B01AX?
Method-of-use and formulation/salt or solid-state patents most commonly constrain generic label entry and bioequivalence.
2) Do Paragraph IV certifications in antithrombotics usually target composition-of-matter or method-of-use patents?
Both, but method-of-use patents are a frequent late-stage blocker when labels cannot be cleanly carved out.
3) How does pediatric exclusivity change entry timing for B01AX antithrombotics?
When applicable, it can extend the effective entry window by adding time after the relevant patent expiration trigger.
4) What manufacturing-related IP barriers can prevent “at-risk” generic launch after compound patent expiry?
Process claims and controls tied to producing a specific salt/polymorph or solid-state profile can still support injunction leverage.
5) Are biosimilar frameworks relevant to B01AX competitive planning?
Only if a specific B01AX-mapped product is biologic. For most planning, small-molecule ANDA dynamics dominate.
References
- FDA. Orange Book: Approved Drug Products with Therapeutapeutic Equivalence Evaluations. (US FDA).
- FDA. Guidance for Industry: Patent Certifications for ANDAs (Paragraph IV Certification). (US FDA).
- 21 U.S.C. § 355 (j) and 35 U.S.C. § 271 (Hatch-Waxman and infringement standards).
- FDA. Drug Development and Drug Interactions: Regulatory Exclusivity and Pediatric Exclusivity information. (US FDA).
More… ↓
